KC-3099

CHOK1-TMEFF2-High Cell Line

×
34126
Home » CHOK1-TMEFF2-High Cell Line

Background of CHOK1-TMEFF2-High Cell Line

TMEFF2 (Transmembrane protein with EGF-like and two follistatin-like domains 2), also known as TENB2 or TPEF, is a type-I transmembrane proteoglycan primarily expressed in the prostate and central nervous system. It plays a complex dual role in cell signaling, acting as a neuroprotective survival factor in the brain while modulating the AKT and MAPK pathways in malignancies. In prostate cancer, TMEFF2 is significantly overexpressed and androgen-regulated, making it a critical diagnostic biomarker and therapeutic target. Current drug development focuses on Antibody-Drug Conjugates (ADCs) and bispecific T-cell engagers (TCEs); for instance, recent clinical trials for candidates like JNJ-70218902 (a T-cell redirecting antibody) have explored its potential in treating metastatic castration-resistant prostate cancer (mCRPC).

Specifications

Catalog NumberKC-3099
Cell Line NameCHOK1-TMEFF2-High Cell Line
NCBI/UniProt Accession NumberNM_016192.4
Clone Number3#
Host Cell LineCHOK1
DescriptionStable CHOK1 cell line expressing exogenous human TMEFF2 gene in high level
QuantityOne vial of frozen cells (≥2×106 cells)
StabilityStable in culture over a minimum of 10 passages
ApplicationDrug screening and biological assays
Freezing Medium70% RPMI1640 + 20% FBS + 10% DMSO
Propagation MediumRPMI1640 + 10% FBS + 10μg/mL Puromycin
Selection MarkerPuromycin
MorphologyEpithelial
SubcultureSplit saturated culture 1:4-1:8 every 2-3 days
Incubation37 °C with 5% CO2
StorageLiquid nitrogen immediately upon receiving
Doubling TimeApproximately 30 hours
Mycoplasma StatusNegative
In Vivo ValidationNA

Cell Line Generation

CHOK1-TMEFF2-High Cell Line was generated using a lentiviral vector expressing the human TMEFF2 sequence.

Characterization

Figure 1: Characterization of human TMEFF2 overexpression in the CHOK1-TMEFF2-High stable high level clone using FACS.

Figure2: Characterization of endogenous TMEFF2 expression in CHOK1 using FACS.

Cell Resuscitation

  1. Pre-warm complete culture medium (basal medium and 10% FBS) in a 37°C water bath.
  2. Rapidly thaw the cryovial in a 37°C water bath for 1-2 minutes with gentle agitation.
  3. Transfer the vial to a biosafety cabinet, and disinfect the exterior with 70% ethanol.
  4. Aseptically transfer the cell suspension dropwise into a sterile centrifuge tube containing 9.0 mL of pre-warmed complete medium.
  5. Centrifuge at approximately 125 × g for 5–7 minutes at room temperature, carefully aspirate the supernatant without disturbing the cell pellet.
  6. Gently resuspend the pellet in an appropriate volume of complete medium and transfer the suspension into a T25 flask.
  7. Incubate the flask in a 37°C in a humidified 5% CO2 incubator.
  8. Assess cell viability and morphology after 24 hours. If cells appear healthy, replace the medium with fresh medium supplemented with the appropriate selective antibiotic.
  9. Subculture the cells at a ratio of 1:4-1:8 every 2-3 days upon reaching 80%–90% confluency.

Cell Freezing

  1. Prepare the freezing medium (70% basal medium, 20% FBS and 10% DMSO) freshly before use.
  2. Pre-chill the freezing medium on ice and label the cryovials accordingly.
  3. Transfer the cell suspension to a sterile conical tube and perform a cell count to determine total viability and density.
  4. Centrifuge the cells at 250×g for 5 minutes at room temperature; carefully aspirate the supernatant.
  5. Gently resuspend the cell pellet in chilled freezing medium, ensuring a minimum cell density of 3×106 cells/mL.
  6. Aliquot 1 mL of the cell suspension into each pre-labeled cryovial.
  7. Place the cryovials into a CoolCell® container and store at -80°C overnight for controlled-rate cooling.
  8. Transfer the cryovials to the liquid nitrogen for long-term storage the following day.

References

1. Masood, Motasim et al. “TMEFF2: A Transmembrane Proteoglycan with Multifaceted Actions in Cancer and Disease.” Cancers vol. 12,12 3862. 21 Dec. 2020, doi:10.3390/cancers12123862
2. Gao, Lingling et al. “TMEFF2 is a novel prognosis signature and target for endometrial carcinoma.” Life sciences vol. 243 (2020): 116910. doi:10.1016/j.lfs.2019.116910
3. Xie, Sidi et al. “TMEFF2 promoter hypermethylation is an unfavorable prognostic marker in gliomas.” Cancer cell international vol. 21,1 148. 4 Mar. 2021, doi:10.1186/s12935-021-01818-x
4. Calvo, Emiliano et al. “A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer.” The oncologist vol. 30,1 (2025): oyae313. doi:10.1093/oncolo/oyae313

Use License Agreement

Research Use Only.
Not for use in diagnostic procedures or therapeutic applications.
Redistribution of the cell line or its derivatives is prohibited without prior written permission from Kyinno Biotechnology.